Preserving a Virtuous Cycle: The Economics of Biopharmaceutical Innovation

Over the past 40 years, the United States has crafted the world’s leading biopharmaceutical innovation ecosystem by fostering a favorable public policy environment that stimulates private sector-driven life-sciences innovation.

Watch the release event of a new report that examines the dynamics that underpin the economics of biopharmaceutical innovation and how to maintain a supportive environment that keeps the United States in the lead of life-sciences innovation. The report and event examined biopharmaceutical innovation and increased U.S. life expectancy revenues and profitability of key actors in the supply chain, from manufacturers to middlemen; and how an effective combination of “push” and “pull” innovation policies can maximally support life-sciences innovation.